Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Anlotinib Hydrochloride Combined With Capeox in the Neoadjuvant Treatment of Locally Advanced Rectal cancer-a Prospective, Open, Single Center and Randomized Controlled Phase Ⅱ Clinical Trial

NCT04620473 is registered in ClinicalTrials.gov with Shanghai Minimally Invasive Surgery Center as lead sponsor.

NCT NCT04620473
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04620473 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Anlotinib Hydrochloride Combined With Capeox in the Neoadjuvant Treatment of Locally Advanced Rectal cancer-a Prospective, Open, Single Center and Randomized Controlled Phase Ⅱ Clinical Trial
Lead sponsor
Shanghai Minimally Invasive Surgery Center
Phase
Phase 2
Overall status
Withdrawn
Start date
November 1, 2023
Completion date
October 1, 2024
Enrollment
0 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

anlotinib, neoadjuvant treatment, rectal cancer